Related Experiment Video
Updated: Feb 6, 2026
08:47
RNA Isolation from Mouse Pancreas: A Ribonuclease-rich Tissue
Published on: August 2, 2014
28.4K
Ribonucleases as Drug Targets.
Emanuele Canestrari1, Zain Paroo1
1Department of Pharmacology, University of Illinois at Chicago, Chicago, IL 60612, USA.
Trends in Pharmacological Sciences
|August 27, 2018
Summary
New drug targets are urgently needed. Analysis revealed 122 human ribonucleases, critical signaling targets that can be leveraged for novel RNA-based therapeutics to improve patient outcomes.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- There is a critical need for novel drug targets across various disease indications.
- The scarcity of effective drug targets leads to numerous drugs with limited clinical benefit.
- Advances in RNA biology offer new therapeutic targets, but challenges remain for nucleic acid-based drugs.
Purpose of the Study:
- To identify and characterize ribonucleases as a potential class of drug targets.
- To explore the therapeutic potential of targeting ribonucleases for RNA-related diseases.
- To expand therapeutic options by developing novel mechanisms of action.
Main Methods:
- Analysis of the human proteome to identify all encoded ribonucleases.
- Bioinformatic and biochemical characterization of the identified ribonucleases.
- Comparative analysis with other enzyme classes (kinases, proteases, epigenetic enzymes).
Main Results:
- Identified 122 distinct ribonucleases in the human proteome.
- The identified ribonucleases play a crucial role in regulating the transcriptome.
- These enzymes represent a conserved and essential component of cellular RNA processing.
Conclusions:
- Ribonucleases constitute a druggable target class with significant therapeutic potential.
- Targeting ribonucleases can capitalize on RNA mechanisms of disease for novel therapies.
- Developing therapies against ribonucleases may lead to improved patient outcomes by expanding treatment options.
Related Concept Videos
01:26Targets for Drug Action: Overview
10.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.3K
01:25Pharmacokinetics: Drug–Drug Interactions
448
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
448
02:57Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
162
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
162
01:26FDA Approved Drugs: Changes to Approved Drugs
270
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
270
01:27Factors Influencing Drug Absorption: Drug Dissolution
1.2K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.2K